News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevi Therapeuitcs Commences Clinical Study of Nalbuphine ER


5/6/2013 10:18:46 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi”) a drug development company focused on developing Nalbuphine ER for chronic pruritus, announced today that it has commenced a Phase 1, open-label study to characterize and compare the pharmacokinetics, safety and tolerability of escalating oral doses of nalbuphine hydrochloride extended release tablets in end-stage renal disease patients on hemodialysis as compared to healthy control subjects. The study will include 20 subjects and top-line data is expected by year-end.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES